Self-Efficacy and Peer Support Enhance the Effectiveness of Disease Management in Diabetes Type 2 (SPEED)

Effectiveness of a peer support program versus care as usual in disease management regarding improvement of metabolic control and diabetes management self-efficacy: a cluster-randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10291077

Enrollment

330

Registered

2010-11-17

Start date

2010-06-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus type 2 Nutritional, Metabolic, Endocrine Non-insulin-dependent diabetes mellitus

Interventions

1. Intervention group: Peer support group meetings and exercise modules (1h per week). Patients will be encouraged to further daily exercising. The aim is to achieve at least an exercise level of 100

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with diabetes mellitus type 2 (American Diabetes Association [ADA]/World Health Organization [WHO] criteria) 2. Currently enrolled in the disease management programme (DMP) called "Therapie aktiv" 3. Aged greater than 18 years, either sex

Exclusion criteria

Exclusion criteria: 1. Refusal or withdrawal of consent 2. Dementia or major psychiatric illness 3. Advanced neoplastic disease or other diseases with drastically reduced life expectancy

Design outcomes

Primary

Measure	Time frame
Current primary outcome measures as of 12/07/2013: Decrease in HbA1c in the intervention group compared to controls, to be measured between 01/10/2010-31/07/2011 (baseline) and 01/10/2010-31/07/2013 Previous primary outcome measures: Decrease in HbA1c in the intervention group compared to controls, to be measured between 01/10-31/12/2010 (baseline) and 01/10-31/12/2012 (end of intervention).	—

Secondary

Measure	Time frame
Current secondary outcome measures as of 12/07/2013: 1. Higher quality of life 2. Improved control of cardiovascular risk factors (hypertension, hyperlipidemia) 3. Lowering of global cardiovascular risk 4. Weight (body mass index [BMI]) reduction 5. Increased smoking cessation The secondary outcomes will be measured between 01/10/2010-31/07/2011 (baseline) and 01/10/2010-31/07/2013 (end of intervention). Previous secondary outcome measures: 1. Improved diabetes management self-efficacy 2. Higher quality of life 3. Improved control of cardiovascular risk factors (hypertension, hyperlipidemia) 4. Lowering of global cardiovascular risk 5. Weight (body mass index [BMI]) reduction 6. Increased smoking cessation The secondary outcomes will be measured between 01/10-31/12/2010 (baseline) and 01/10-31/12/2012 (end of intervention).	—

Measure

Time frame

Current secondary outcome measures as of 12/07/2013: 1. Higher quality of life 2. Improved control of cardiovascular risk factors (hypertension, hyperlipidemia) 3. Lowering of global cardiovascular risk 4. Weight (body mass index [BMI]) reduction 5. Increased smoking cessation The secondary outcomes will be measured between 01/10/2010-31/07/2011 (baseline) and 01/10/2010-31/07/2013 (end of intervention). Previous secondary outcome measures: 1. Improved diabetes management self-efficacy 2. Higher quality of life 3. Improved control of cardiovascular risk factors (hypertension, hyperlipidemia) 4. Lowering of global cardiovascular risk 5. Weight (body mass index [BMI]) reduction 6. Increased smoking cessation The secondary outcomes will be measured between 01/10-31/12/2010 (baseline) and 01/10-31/12/2012 (end of intervention).

—

Countries

Austria

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 3, 2026